The New BioPharma Playbook: Seven Technologies Defining Drug Development in 2026

A common theme emerging across oncology, infectious disease, neurology, and cell therapy, is the evolution of biopharmaceuticals from single-function molecules into increasingly sophisticated therapeutic platforms capable of performing multiple tasks simultaneously. Some deliver cytotoxic payloads directly into cancer cells. Others engage multiple immune pathways through a single antibody. Still others program immune cells inside the body or cross biological barriers that have historically limited treatment options.

The result is a new generation of large-molecule medicines designed to take treatment a step further. These therapies not only recognize a target but also actively manipulate biological systems. Several of 2026's most closely watched programs illustrate this shift, including:

• Pfizer’scommitment of up to $10.5 billion to secure rights to IBI343, Innovent's CLDN18.2-targeting antibody-drug conjugate (ADC)¹˒²
• Summit Therapeutics’positive overall survival data for the protein 1 (PD-1), vascular endothelial growth factor (VEGF), bispecific antibody ivonescimab in squamous non-small cell lung cancer^3,4
• GSK's demonstrated functional cure rates of bepirovirsen approaching 20% in chronic hepatitis B, a disease affecting nearly 300 million people worldwide.^5,1

Developers of in vivo chimeric antigen receptor T-cell CAR-T platforms are working to eliminate ex vivo manufacturing, a current limitation in cell therapy.^6,7

These advances suggest that 2026 may be remembered less for any individual product and more for the maturation of several biotherapeutic technologies that could play a role in reshaping drug development over the next decade.

How are ADCs becoming precision delivery systems?

Top therapy: IBI343 (Innovent Biologics/Pfizer)

Few oncology assets generated more attention in 2026 than IBI343, the CLDN18.2-targeting ADC that became the centerpiece of Pfizer's $10.5 billion licensing agreement with Innovent Biologics.¹˒² The size of the transaction reflects growing industry confidence in CLDN18.2 as a commercially significant target in gastrointestinal oncology.

The molecule combines a CLDN18.2-targeted antibody with a topoisomerase inhibitor payload, allowing selective delivery of cytotoxic therapy to gastrointestinal tumors expressing the target. The asset is being evaluated across gastric, gastroesophageal junction, and pancreatic cancers.

Runner-up: deruxtecan (Dato-DXd)

Datopotamab deruxtecan continues to generate momentum through the TROPION clinical program in lung and breast cancer^8,9 The TROP2-directed ADC represents how modern conjugates are evolving beyond targeted delivery toward broader platform applications across multiple tumor types.

Why are multifunctional antibodies emerging as the next evolution of immunotherapy?

Top therapy: ivonescimab

Among the year's significant clinical developments were the Phase 3 HARMONi-6 results for ivonescimab.^3,4 Unlike conventional monoclonal antibodies, ivonescimab simultaneously targets PD-1 and VEGF within a single molecular construct. This dual-action approach seeks to coordinate immune activation and angiogenesis inhibition simultaneously. Positive overall survival findings have intensified industry interest in multifunctional antibody architectures capable of combining multiple validated mechanisms into one therapeutic agent.

Runner-up: zanidatamab

Zanidatamab represents another example of increasingly sophisticated antibody engineering. Rather than targeting a single HER2 epitope, the molecule binds two distinct HER2 domains simultaneously. ^10,11 Publication of positive Phase 3 HERIZON-GEA-01 results in The New England Journal of Medicine further strengthened its position as a potential new standard of care in HER2-positive gastroesophageal cancer.¹¹

Can T-cell redirecting therapies finally break through in solid tumors?

Top therapy: xaluritamig (AMG 509)

T-cell engagers have transformed certain hematologic malignancies, but success in solid tumors has remained elusive. Xaluritamig may represent one of the strongest opportunities to change that narrative. The STEAP1-targeted T-cell engager is currently being evaluated in the Phase 3 XALute study for metastatic castration-resistant prostate cancer.¹² A successful outcome could establish one of the first broadly successful T-cell engager platforms in a common solid tumor.

Runner-up: CBX-663

Crossbow Therapeutics' CBX-663 highlights growing enthusiasm for T-cell receptor (TCR)-mimetic biologics.¹³ By targeting intracellular proteins presented through MHC molecules, these therapies potentially expand the druggable cancer proteome beyond conventional surface antigens.

Will in vivo cell therapy make CAR-T more accessible?

Top therapy: in vivo CAR-T platforms

Traditional CAR-T therapy requires individualized manufacturing that limits scalability and access. In vivo CAR-T developers such as Kelonia Therapeutics are attempting to eliminate that bottleneck by delivering CAR instructions directly into patients using engineered vectors or lipid nanoparticle systems.^6,7 If successful, this approach reduces manufacturing complexity and expands access beyond specialized treatment centers.

Runner-up: Ori-C101

Oricell Therapeutics' GPC3-targeted CAR-T therapy demonstrated encouraging activity in hepatocellular carcinoma at the 2026 ASCO Annual Meeting.¹⁴ Because solid tumors have persistently resisted CAR-T approaches, programs like Ori-C101 remain important proof-of-concept studies for the broader field.

Are cancer vaccines finally reaching clinical relevance?

Top therapy: Nous-209

Cancer vaccines are experiencing renewed interest as advances in neoantigen biology improve target selection strategies. Nous-209 utilizes a shared neoantigen approach targeting recurrent frameshift mutations found across Lynch syndrome-associated cancers.¹⁵ Unlike fully personalized vaccine approaches, the platform offers potential scalability while maintaining tumor specificity.

Runner-up: adagloxad simolenin

Adagloxad simolenin remains one of the most advanced therapeutic cancer vaccine programs targeting the Globo H antigen.¹⁶ Upcoming phase 3 data may help determine whether vaccine-induced anti-tumor immune responses can consistently translate into meaningful clinical outcomes.

Can large-molecule medicines deliver functional cures for chronic disease?

Top therapy: bepirovirsen

Perhaps no biologic on this list carries greater global public health implications than bepirovirsen, GSK's antisense oligonucleotide. Chronic hepatitis B affects approximately 296 million people worldwide and remains a leading cause of cirrhosis and liver cancer. Current therapies generally suppress disease but rarely achieve functional cure. Phase 3 data for bepirovirsen demonstrated functional cure rates approaching 20% in some patient populations.^5,17 The findings earned bepirovirsen both FDA breakthrough therapy and priority review designations. The results represent an important advancement for infectious disease in 2026.

Runner-up: VAX-31

With VAX-31, Vaxcyte seeks to expand pneumococcal protection through a 31-valent conjugate vaccine.¹⁸The program highlights continued innovation in preventive biologics and the pursuit of broader population-level disease protection.

Are blood-brain barrier technologies unlocking the next frontier of neurology?

Top platform: blood-brain barrier shuttle antibodies

A significant development in neurology may be an enabling technology rather than a single therapeutic product. Blood-brain barrier shuttle platforms exploit endogenous transport pathways to move biologic therapies across the blood-brain barrier more efficiently than traditional antibodies.¹⁹˒²⁰ Companies including Denali Therapeutics and Roche are advancing programs designed around this concept.

Runner-up: next-generation anti-amyloid antibodies

Developers are increasingly combining shuttle technologies with anti-amyloid antibodies to improve central nervous system exposure while potentially reducing safety concerns associated with existing therapies. If successful, these approaches could substantially reshape future Alzheimer's disease treatment strategies.

Will 2026 represent a turning point for large-molecule innovation?

The most consequential question facing biopharmaceutical development is no longer whether large-molecule medicines work. That question was answered decades ago. Today’s question is how much biological complexity a single therapy can be engineered to manage.

The therapies attracting the greatest attention in 2026 share a common design philosophy. They combine mechanisms, redirect immune cells, deliver payloads, reprogram biology, or overcome physiological barriers that once limited therapeutic reach.

Whether these individual programs ultimately fail or succeed, they signal a broader transition. The next era of biopharmaceuticals will be defined less by targets and more by technology platforms capable of solving increasingly complex biological problems. In that sense, 2026 may represent not simply another productive year for biopharma, but the beginning of a new technological chapter for large-molecule drug development.

References

1. Pfizer and Innovent Biologics sign global collaboration agreement for IBI343. (2026 May 28). Pfizer Inc. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic
2. Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market. (2025 Oct 21). PR Newswire. https://www.prnewswire.com/news-releases/innovent-biologics-announces-global-strategic-partnership-with-takeda-to-bring-innovents-next-gen-io-backbone-therapy-and-adc-molecules-to-the-global-market-302590770.html
3. Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China. (2026 May 31). Summit Therapeutics. https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-with-Chemotherapy-Demonstrated-a-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Tislelizumab-Plus-Chemotherapy-in-1L-Treatment-of-Patients-with-Squamous-NSCLC-in-the-HARMONi-6-Study-Conducted-by-Akeso-in-China/default.aspx
4. ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%. (2026 May 31). Fierce Pharma. https://www.fiercepharma.com/pharma/asco-akeso-ivonescimab-bests-pd-1-inhibitor-squamous-nsclc-overall-survival
5. Hou, J., et al. (2026 May 28). Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Eng J Med. https://www.nejm.org/doi/full/10.1056/NEJMoa2515131
6. Rurik JG, et al. (2022 Jan 6). CAR T cells produced in vivo to treat cardiac injury. Science. https://www.science.org/doi/10.1126/science.abm0594
7. Kelonia Therapeutics to Present Updated Clinical Data at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2026 Congress. (2026 May 21). Kelonia Therapeutics. https://keloniatx.com/kelonia-therapeutics-to-present-updated-clinical-data-at-2026-american-society-of-clinical-oncology-asco-annual-meeting-and-european-hematology-association-eha-2026-congress/
8. Datroway (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer. (2025 Jan 17). Nasdaq. https://www.nasdaq.com/press-release/datrowayr-datopotamab-deruxtecan-dlnk-approved-us-patients-previously-treated?utm_source=chatgpt.com
9. Meric-Bernstam, F. et al. (2025 Feb 18). Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. J Clin Oncol. DOI:10.1200/JCO.2025.43.5_suppl.663
10. HERIZON-GEA-01 Phase III study results. (2026 May 27). Jazz Pharmaceuticals. https://investor.jazzpharma.com/news-releases/news-release-details/phase-3-herizon-gea-01-results-published-new-england-journal
11. Shitara K, Elimova E, Liu T, et al. (2026 May 28). HERIZON-GEA-01 Investigators. Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/42202319/
12. Kelly WK, Morris MJ, Horvath L, et al. (2025 May 28). Trial in progress (XALute): Phase 3 study of xaluritamig versus investigator's choice of cabazitaxel or second androgen receptor-directed therapy in post-taxane metastatic castration-resistant prostate cancer (mCRPC). J Clin Onc. https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS5118
13. Crossbow Therapeutics. (2025 Jul 21). Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies. Business Wire. https://www.businesswire.com/news/home/20250723684640/en/Crossbow-Therapeutics-Nominates-its-Second-Development-Candidate-CBX-663-a-Broadly-Acting-Therapeutic-for-a-Wide-Range-of-Solid-and-Hematologic-Malignancies
14. ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential. (2026 Jun 1). First Word Pharma. https://firstwordpharma.com/story/7509888
15. Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers. (2026 Jun). Globe News Wire. https://www.globenewswire.com/news-release/2026/06/01/3304206/0/en/nouscom-receives-u-s-fda-fast-track-designation-for-nous-209-a-novel-immunotherapy-for-the-prevention-of-lynch-syndrome-associated-cancers.html
16. Huang, C. S., et al. (2020 Jul). Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. (2020 Jul). Journal for immunotherapy of cancer.https://pubmed.ncbi.nlm.nih.gov/32718986/
17. Hou J, Lim SG, Buti M, Yuen MF, et al. (2026 May 28). B-Well Study Group. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. https://www.nejm.org/doi/abs/10.1056/NEJMoa2515131?utm_source=chatgpt.com
18. Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate. (2026 March 18). Vaxcyte. https://investors.vaxcyte.com/news-releases/news-release-details/positive-vax-31-phase-12-adult-data-published-lancet-infectious/
19. Pardridge WM. (2025 Jan). The blood-brain barrier: bottleneck in brain drug development. NeuroRx. https://pubmed.ncbi.nlm.nih.gov/15717053/
20. Niewoehner, J., et al.(2014 Jan. 8). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. https://pubmed.ncbi.nlm.nih.gov/24411731/